AVXL logo

Anavex Life Sciences


AVXL: Anavex Life Sciences Corp is a clinical-stage biopharmaceutical company engaged in the development of differentiated therapeutics by applying precision medicine to central nervous system diseases with high unmet need. It analyzes genomic data from clinical studies to identify biomarkers, which are used to select patients that will receive the therapeutic benefit for the treatment of neurodegenerative and neurodevelopmental diseases. Its lead compound ANAVEX 2-73 is being developed to treat Alzheimer's disease, Parkinson's disease, and potentially other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder. The company's operating segment is into developing novel therapies for the management of CNS diseases.


Show AVXL Financials

Consumer Interest
SEC Filings

Recently reported changes by institutional investors

Quarterly net insider trading by AVXL's directors and management

Government lobbying spending instances

Quiver Logo

No Corporate Lobbying instances for this ticker

Corporate Lobbying Dashboard
U.S. Patents

New patents grants

Quiver Logo

No new patents for this ticker

U.S. Patents Dashboard
Government Contracts

Federal grants, loans, and purchases

Quiver Logo

No Government Contracts for this ticker

Government Contracts Dashboard

Number of mentions of AVXL in WallStreetBets Daily Discussion


Recent insights relating to AVXL

CNBC Recommendations

Recent picks made for AVXL stock on CNBC

Top ETF Holders

ETFs with the largest estimated holdings in AVXL

Corporate Flights

Flights by private jets registered to AVXL